Lavipharm (LAVI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Sep, 2026Executive summary
Consolidated sales prior to clawback and rebate rose 24.1% year-over-year to €38.5 million.
EBITDA from continuing operations increased by 5.2% compared to H1 2025.
Net earnings from continuing operations, excluding one-time income, grew 41.3% year-over-year.
Financial highlights
Consolidated sales after clawback and rebates reached €34.4 million, up 28.9% from H1 2025.
Adjusted EBITDA was €7.1 million, down 7.7% due to a €0.9 million one-off gain in H1 2025.
Earnings after taxes were €2.4 million, compared to €2.6 million in H1 2025.
Outlook and guidance
Sales in H2 2026 are expected to be significantly higher than H1, both domestically and internationally.
DUROGESIC® commercial distribution to begin in early October, not included in H1 estimates.
Latest events from Lavipharm
- Net profit after tax surged to €7.7m on stable sales and deferred tax asset recognition.LAVI
Q2 2024 - After-tax profit soared 338.6% on strong sales and a deferred tax asset recognition.LAVIQ3 2024
- Net profit surged 380% on strong sales, strategic deals, and deferred tax gains.LAVIQ4 2024
- EBITDA and net profit surged, led by domestic sales, despite a temporary export decline.LAVIQ1 2025
- Sales and EBITDA up, net profit down on tax effect; strong H2 growth expected.LAVIQ2 2025
- Adjusted EBITDA up 11.2% and domestic prescription sales surged, with Q4 rebound expected.LAVIQ3 2025
- Sales and EBITDA surged in 2025, driven by acquisitions and international expansion.LAVIQ4 2025